Significance of spatial organization of chromosomes in the progression of acute myeloid leukemia

Chen W, Zheng R, Zeng H, et al. The incidence and mortality of major cancers in China, 2012. Chin J Cancer. 2016;35(1):73.

Kang ZJ, Liu YF, Xu LZ, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35(1):48.

Qin YZ, Wang Y, Zhu HH, et al. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t (8; 21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Chin J Cancer. 2016;35(1):46.

Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, et al. Patients with t (8; 21)(q22; q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767–75.

Morschhauser F, Cayuela J, Martini S, Baruchel A, Rousselot P, Socie G, et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t (8; 21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol. 2000;18(4):788.

Perea G, Lasa A, Aventin A, Domingo A, Villamor N, de Llano MPQ, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics t(8; 21) and inv (16). Leukemia. 2006;20(1):87–94.

Coustan-Smith E, Campana D. Should evaluation for minimal residual disease be routine in acute myeloid leukemia? Curr Opin Hematol. 2013;20(2):86–92.

Tian X, Wang Y, Zhao F, Liu J, Yin J, Chen D, et al. A new classification of interphase nuclei based on spatial organizations of chromosome 8 and 21 for t(8;21) (q22;q22) acute myeloid leukemia by three-dimensional fluorescence in situ hybridization. Leuk Res. 2015;39(12):1414–20.